# A Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease

> **NCT03462121** · PHASE2 · COMPLETED · sponsor: **Regenera Pharma Ltd** · enrollment: 83 (actual)

## Conditions studied

- Mild to Moderate Dementia Due to Alzheimer's Disease
- With or Without Coexisting Cerebrovascular Disease

## Interventions

- **DRUG:** RPh201
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03462121
- **Lead sponsor:** Regenera Pharma Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-01
- **Primary completion:** 2019-12-28
- **Final completion:** 2020-03-30
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2020-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03462121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03462121, "A Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03462121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*